FIELD: biotechnology.
SUBSTANCE: humanized monoclonal antibody is obtained which comprises a heavy chain variable region comprising an amino acid sequence selected from SEQ ID NO: 7, 12, 13, 15 and 16, and a light chain variable region comprising the amino acid sequence SEQ ID NO: 14, and also a host cell that expresses the nucleic acid that encodes it.
EFFECT: invention effectively suppresses the T-cell-mediated response in a subject.
13 cl, 26 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY MEANS OF GLYCOENGINEERING | 2014 |
|
RU2711935C2 |
| HYPERGLYCOSYLATED BINDING POLYPEPTIDES | 2014 |
|
RU2708314C2 |
| SITE-SPECIFIC ANTIBODY-DRUG CONJUGATION BY GLYCOENGINEERING | 2014 |
|
RU2831409C2 |
| CONSTRUCTED ANTI-TSLP ANTIBODY | 2010 |
|
RU2575039C2 |
| APOPTOTIC ANTIBODIES AGAINST IgE | 2008 |
|
RU2500686C2 |
| ANTIBODIES TO OX-2/CD200 AND THEIR APPLICATION | 2007 |
|
RU2520088C2 |
| ANTIBODIES AGAINST HUMAN IL33R AND USE THEREOF | 2012 |
|
RU2597288C2 |
| ANTIBODIES AGAINST OX40 AND METHODS OF THEIR APPLICATION | 2012 |
|
RU2562874C1 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
Authors
Dates
2017-09-11—Published
2012-09-12—Filed